-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Aldesleukin in Systemic Lupus Erythematosus
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Aldesleukin in Systemic Lupus Erythematosus report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Aldesleukin in Systemic Lupus Erythematosus Drug Details: ILT-101 is under development...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – CURN-399 in Asthma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CURN-399 in Asthma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CURN-399 in Asthma Drug Details: CURN-399 is under development for the treatment of...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – MG01-T517 in Allergic Asthma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MG01-T517 in Allergic Asthma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MG01-T517 in Allergic Asthma Drug Details: MG01-T517 is under development for the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Vidutolimod in Merkel Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vidutolimod in Merkel Cell Carcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vidutolimod in Merkel Cell Carcinoma Drug Details: CMP-001 (CYT-003) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KAND-567 in Fallopian Tube Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - KAND-567 in Fallopian Tube Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. KAND-567 in Fallopian Tube Cancer Drug Details: KAND-567 (AZD-8797) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Omalizumab in Food Allergy
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Omalizumab in Food Allergy Drug Details: Omalizumab (Xolair, Bolstran) is a recombinant DNA-derived humanized IgG1-kappa...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Omalizumab in Peanut Allergy
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Omalizumab in Peanut Allergy Drug Details: Omalizumab (Xolair, Bolstran) is a recombinant DNA-derived humanized IgG1-kappa...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Omalizumab in Milk Allergy
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Omalizumab in Milk Allergy Drug Details: Omalizumab (Xolair, Bolstran) is a recombinant DNA-derived humanized IgG1-kappa...
-
Product Insights
Rhino-Conjunctivitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Rhino-Conjunctivitis - Drugs In Development, 2023’, provides an overview of the Rhino-Conjunctivitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Rhino-Conjunctivitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Allergic Rhino-Conjunctivitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Allergic Rhino-Conjunctivitis - Drugs In Development, 2023’, provides an overview of the Allergic Rhino-Conjunctivitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Allergic Rhino-Conjunctivitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...